middl
east
respiratori
syndrom
coronaviru
merscov
spread
countri
infect
peopl
sinc
first
outbreak
saudi
arabia
high
fatal
rate
novel
coronaviru
persist
wide
spread
infecti
anim
reservoir
gener
tremend
global
public
health
concern
howev
licens
therapeut
agent
vaccin
merscov
current
avail
limit
enter
clinic
trial
among
potenti
target
merscov
spike
glycoprotein
wellstudi
due
critic
role
mediat
viral
entri
induc
protect
antibodi
respons
infect
individu
notabl
studi
includ
recent
discoveri
monoclon
antibodi
develop
candid
vaccin
glycoprotein
structur
character
merscov
protein
bound
monoclon
antibodi
provid
insight
mechan
humor
immun
respons
merscov
infect
current
review
aim
highlight
develop
discuss
possibl
hurdl
strategi
translat
discoveri
ultim
medic
intervent
merscov
infect
rapid
emerg
dissemin
infecti
diseas
taken
heavi
toll
human
sinc
begin
twentyfirst
centuri
one
wellknown
exampl
outbreak
sever
acut
respiratori
syndrom
sar
winter
caus
novel
coronaviru
sarscov
distinct
contrast
mild
human
coronavirus
infect
sarscov
frequent
result
sever
symptom
includ
fever
dri
cough
short
breath
pneumonia
transmiss
sarscov
primarili
person
person
case
occur
health
care
set
lack
adequ
infect
control
precaut
sar
outbreak
sever
consequ
countri
region
infect
peopl
worldwid
fatal
rate
approxim
still
vaccin
therapeut
specif
sarscov
avail
year
sar
outbreak
hard
imagin
catastroph
would
sarscov
hit
human
commun
sarscov
remain
mysteri
loos
cannon
anoth
novel
coronaviru
emerg
saudi
arabia
later
known
middl
east
respiratori
syndrom
coronaviru
merscov
fatal
rate
merscov
infect
approxim
new
case
well
associ
death
continu
aris
date
despit
case
attribut
humantohuman
transmiss
merscov
appear
transmit
effici
among
human
unless
close
contact
exact
sourc
merscov
rout
transmiss
human
still
remain
uncertain
dromedari
camel
believ
anim
reservoir
merscov
isol
camel
almost
ident
human
mani
domest
camel
seroposit
merscov
review
furthermor
current
evid
strongli
suggest
bat
origin
sourc
merscov
mani
coronavirus
phylogenet
relat
merscov
origin
bat
includ
mersrel
coronavirus
also
shown
abl
engag
cellular
receptor
merscov
ad
evid
bat
origin
theori
howev
yet
direct
evid
isol
merscov
bat
review
great
effort
made
develop
prevent
therapeut
intervent
merscov
infect
particular
monoclon
antibodi
vaccin
target
spike
glycoprotein
major
area
focu
due
critic
role
mediat
viral
entri
potenti
induc
protect
antibodi
respons
infect
individu
far
twenti
monoclon
antibodi
nanomolar
neutral
activ
report
mani
vaccin
candid
underway
preclin
clinic
studi
review
aim
captur
current
advanc
discuss
possibl
strategi
translat
discoveri
ultim
medic
intervent
merscov
infect
merscov
belong
genu
betacoronaviru
coronavirida
famili
envelop
singlestrand
positivesens
rna
viru
helic
capsid
structur
figur
genom
merscov
around
kb
long
encod
structur
protein
spike
envelop
membran
nucleocapsid
nonstructur
protein
figur
c
like
coronavirus
merscov
use
spike
glycoprotein
interact
cellular
receptor
enter
target
cell
uniqu
structur
compon
virion
membran
glycoprotein
assembl
trimer
form
larg
protrud
spike
surfac
virion
glycoprotein
typic
type
membran
glycoprotein
consist
globular
domain
ntermin
follow
membraneproxim
domain
transmembran
tm
domain
domain
mediat
viral
attach
contain
rbd
receptor
bind
domain
determin
host
rang
cellular
tropism
merscov
similar
coronavirus
domain
merscov
mediat
membran
fusion
contain
hydrophob
fusion
peptid
fp
nterminu
well
two
heptad
repeat
design
figur
c
copurif
merscov
domain
raj
colleagu
identifi
dipeptidyl
peptidas
also
known
function
cellular
receptor
merscov
merscov
virion
enter
host
airway
cell
respiratori
tract
fusion
either
plasma
endosom
membran
bind
rbd
cell
receptor
trigger
cascad
conform
chang
lead
format
prehairpin
intermedi
hydrophob
expos
allow
fusion
peptid
insert
target
cell
membran
transient
intermedi
refold
stabil
trimer
hairpin
also
call
sixhelix
bundl
structur
bring
target
cell
membran
close
proxim
viral
envelop
result
complet
fusion
process
initi
viru
life
cycl
figur
b
structurebas
design
variou
peptid
abl
block
format
demonstr
potent
inhibit
merscov
replic
spikemedi
cellcel
fusion
show
great
promis
develop
effect
viral
fusion
inhibitor
treat
merscov
infect
among
peptid
effect
multipl
human
coronavirus
apart
merscov
therefor
serv
potenti
pancoronaviru
fusion
inhibitor
recent
structur
studi
prefus
state
spike
protein
merscov
sarscov
provid
insight
spikemedi
membran
fusion
process
merscov
spike
protein
trimer
fold
metast
prefus
conform
virion
surfac
three
domain
fold
steadi
trimer
structur
sit
top
stabil
coil
domain
figur
ab
other
identifi
rbd
sarscov
merscov
found
either
buri
posit
expos
posit
spike
trimer
structur
two
conform
state
rbd
may
distinct
role
receptor
bind
membran
fusion
rbd
posit
posit
bind
cell
receptor
figur
cd
great
steric
clash
observ
neighbor
spike
protom
map
rbd
posit
figur
cd
transform
rbd
buri
expos
state
therefor
prerequisit
receptor
bind
figur
gh
hand
conform
chang
also
seem
open
stabl
cap
structur
sit
core
figur
ef
may
lead
disassoci
trimer
exposur
fusion
apparatu
trigger
membran
fusion
process
gain
better
understand
merscov
interact
cellular
receptor
atom
level
other
determin
crystal
structur
merscov
rbd
bound
extracellular
domain
cellular
receptor
dipeptidyl
peptidas
show
merscov
rbd
consist
core
receptor
bind
subdomain
merscov
rbd
relat
sarscov
rbd
share
high
degre
structur
similar
core
subdomain
notabl
diverg
receptor
bind
subdomain
receptor
bind
subdomain
merscov
rbd
directli
interact
blade
propel
instead
intrins
hydrolas
domain
interfac
consist
buri
surfac
involv
residu
receptor
bind
subdomain
interact
residu
actual
bind
forc
mediat
two
major
bind
patch
patch
repres
buri
surfac
form
ctermin
end
long
loop
connect
strand
blade
patch
occupi
buri
surfac
form
slightli
concav
outer
surfac
far
end
merscov
receptor
bind
subdomain
linker
contain
short
helix
blade
blade
concav
outer
surfac
made
short
strand
ctermin
part
strand
ntermin
part
strand
link
loop
hope
better
understand
atom
detail
spike
glycoprotein
well
interfac
merscov
rbd
provid
structur
basi
ration
design
develop
therapeut
vaccin
merscov
infect
neutral
antibodi
major
compon
protect
immun
viral
infect
human
polyclon
natur
antibodi
respons
vivo
mobil
dynam
complex
mixtur
monoclon
antibodi
mab
work
concert
target
variou
antigen
domain
viral
envelop
glycoprotein
identifi
neutral
mab
constitut
neutral
activ
polyclon
respons
recogn
antigen
domain
therefor
becom
first
crucial
step
toward
gain
better
understand
protect
antibodi
respons
develop
clinic
intervent
method
design
immunogen
capabl
elicit
neutral
antibodi
great
achiev
made
isol
neutral
mab
past
year
use
variou
technolog
platform
figur
till
mab
human
human
antibodi
describ
scientist
world
antibodi
list
chronolog
order
public
tabl
togeth
uniqu
biochem
antivir
properti
merscov
infect
observ
cell
cultur
experiment
anim
model
appar
singl
chain
fragment
variabl
scfv
librari
approach
allow
rapid
discoveri
mab
without
time
constraint
immun
experiment
anim
approach
convalesc
individu
merscov
infect
earliest
mab
report
identifi
screen
nonimmun
human
scfv
librari
ectodomain
glycoprotein
mab
solubl
rbd
glycoprotein
panel
bait
protein
figur
antibodi
demonstr
high
neutral
activ
therefor
wide
use
refer
antibodi
later
studi
antibodi
also
gener
immun
anim
figur
b
sever
group
report
mab
isol
either
wildtyp
inbr
mice
transgen
mice
express
human
antibodyvari
heavi
chain
light
chain
known
human
isol
mice
immun
subcutan
chimer
mab
human
form
h
isol
mice
immun
recombin
rbd
produc
insect
cell
furthermor
two
humanlik
mab
directli
clone
transgen
mice
express
human
version
antibodi
immun
dna
encod
glycoprotein
purifi
recombin
glycoprotein
mab
test
human
mice
model
nonhuman
primat
author
indic
advantag
system
lay
human
compon
antibodi
also
quick
speed
associ
isol
product
sinc
human
optim
step
requir
current
enter
phase
clinic
trial
mab
report
far
target
rbd
region
glycoprotein
rbd
seem
target
antimerscov
antibodi
respons
recent
mab
target
nterminu
domain
ntd
region
contain
rbd
isol
mice
immun
glycoprotein
antibodi
shown
success
block
viru
entri
cell
cultur
model
efficaci
compar
mab
ic
mab
panel
gener
prime
similarli
isol
nonimmun
human
scfv
phage
librari
merscov
protein
rbd
protein
bait
protein
respect
b
monoclon
antibodi
sort
immun
anim
antibodi
isol
mice
immun
indic
vaccin
label
colourcod
box
repres
differ
immunogen
bait
target
protein
antibodi
select
also
list
mice
isol
given
pale
blue
colour
indic
express
human
immunoglobulin
gene
isol
larger
anim
includ
llama
rhesu
macaqu
camel
indic
vaccin
select
criteria
also
shown
ntd
ntermin
domain
fc
fragment
constant
c
monoclon
antibodi
isol
human
survivor
recov
merscov
infect
gener
cultur
b
cell
sort
patient
screen
merscovspecif
antibodi
produc
construct
phage
librari
display
scfv
clone
convalesc
patient
mice
dna
encod
fulllength
glycoprotein
boost
protein
among
two
mab
target
nonrbd
mab
region
mab
respect
nonrbdbind
antibodi
potent
neutral
pseudoand
live
merscov
cell
cultur
also
protect
mous
model
togeth
develop
antibodi
elucid
rbd
may
singl
target
antivir
antibodi
respons
studi
need
elabor
detail
mechan
antibodi
apart
tradit
approach
isol
mab
immun
mice
sever
group
turn
larger
anim
model
antibodi
isol
one
group
immun
rhesu
macaqu
combin
dna
protein
vaccin
isol
panel
mab
includ
target
rbd
nonrbd
region
glycoprotein
potent
neutral
activ
anoth
group
immun
llama
recombin
rbd
screen
nanobodi
librari
highaffin
singl
heavi
chain
antibodi
nanobodyderiv
mab
smaller
molecular
weight
stabl
tradit
antibodi
may
provid
new
option
futur
antibodi
isol
term
close
authent
human
antibodi
approach
compet
base
direct
b
cell
clone
convalesc
individu
one
mab
isol
memori
b
cell
human
survivor
merscov
infect
among
potent
mab
report
neutral
pseudoand
live
virus
mab
isol
human
survivor
describ
convalesc
blood
sampl
becam
avail
includ
figur
c
potent
neutral
activ
merscov
mab
also
test
protect
anim
model
merscov
research
progress
quickli
past
year
mani
mab
test
prophylact
therapeut
protect
efficaci
human
transgen
transduc
mice
model
enter
larg
anim
model
trial
rabbit
nonhuman
primat
nhp
howev
differ
anim
model
establish
among
lab
worldwid
slightli
differ
evalu
end
point
difficult
make
direct
comparison
among
mab
also
true
vitro
evalu
neutral
activitiessinc
differ
cell
line
pseudovirus
neutral
assay
techniqu
util
publish
ic
valu
serv
indirect
refer
comparison
head
head
comparison
experiment
system
would
requir
identifi
protect
mab
combin
mab
merscov
infect
order
proceed
clinic
trial
other
carri
structur
studi
merscov
neutral
antibodi
complex
mersrbd
understand
neutral
mechan
atom
level
figur
base
epitop
reveal
structur
studi
merscov
antibodi
target
rbd
classifi
three
group
figur
b
tabl
first
group
consist
antibodi
interact
ctermin
segment
loop
strand
rbd
heavi
light
chain
figur
b
common
epitop
rbd
includ
residu
loop
residu
also
happen
within
site
patch
merscov
rbd
mediat
interact
carbohydr
moieti
link
therefor
group
antibodi
would
directli
compet
bind
rbd
interf
proteinprotein
proteincarbohydr
interact
rbd
structur
superimposit
also
show
four
antibodi
would
steric
clash
variabl
domain
heavi
chain
propel
domain
simultan
bind
rbd
figur
c
second
group
consist
antibodi
interact
strand
loop
loop
rbd
mainli
heavi
chain
figur
b
common
epitop
consist
phe
although
antibodi
group
group
share
bind
residu
approach
angl
rbd
significantli
differ
shown
figur
c
approach
angl
group
antibodi
closer
rotat
approxim
degre
anticlockwis
group
antibodi
therebi
gener
steric
clash
also
evidenc
larger
overlap
common
epitop
group
antibodi
site
rbd
repres
group
antibodi
exhibit
potent
neutral
activ
mimick
critic
interact
rbd
also
adopt
approach
angl
similar
figur
c
third
group
consist
antibodi
variant
four
residu
replac
figur
b
structur
determin
shown
fab
scfv
share
mode
bind
rbd
figur
b
analysi
complex
structur
show
antibodi
contact
loop
receptorbind
subdomain
rbd
epitop
involv
note
epitop
overlap
site
figur
c
approach
rbd
outsid
site
recogn
uniqu
epitop
differ
previous
report
rbdtarget
antibodi
comparison
rbd
state
reveal
bind
induc
fix
loop
conform
fold
shallow
groov
rbd
interfac
critic
accommod
short
helix
therebi
indirectli
disrupt
interact
rbd
figur
c
differ
epitop
mechan
enabl
synerg
antibodi
includ
rbdtarget
neutral
provid
valuabl
addit
combin
use
antibodi
merscov
infect
addit
aforement
ten
antibodi
target
rbd
near
atom
resolut
cryoem
structur
trimer
merscov
spike
complex
antibodi
also
determin
figur
first
report
antibodi
epitop
consist
glycosyl
solventexpos
loop
resid
connector
domain
subunit
unbound
spike
trimer
structur
loop
larg
disord
wherea
extend
two
surround
six
cdr
complementar
determin
region
mab
upon
antibodi
recognit
figur
e
specif
interact
may
stabil
loop
imped
conform
chang
subunit
essenti
membran
fusion
bind
bind
epitop
subunit
conserv
rbd
among
merscov
isol
shed
light
potenti
broadspectrum
neutral
antibodi
merscov
yet
loop
variabl
sequenc
length
among
differ
virus
even
lineag
c
betacoronavirus
limit
applic
coronavirus
term
pancoronaviru
medic
countermeasur
mcm
recent
develop
fusion
inhibitor
peptid
potenti
candid
peptid
design
target
conserv
region
stem
shown
block
cellcel
fusion
induc
spike
protein
multipl
human
coronavirus
gener
report
merscov
neutral
antibodi
recogn
rbd
subunit
antibodi
highli
potent
neutral
fact
show
rbd
subunit
major
vulner
site
antibodi
recognit
neutral
note
rbd
also
region
natur
occur
mutat
glycoprotein
occur
current
comprehens
studi
antibodi
target
nonrbd
region
spike
glycoprotein
also
includ
mab
target
ntermin
domain
ntd
subunit
well
mab
target
nonrbd
region
subunit
howev
detail
epitop
specif
mechan
still
unclear
antibodi
expect
antibodi
new
neutral
epitop
andor
mechan
would
import
combin
use
antibodi
merscov
infect
although
monoclon
antibodi
show
promis
antivir
effect
cell
cultur
anim
model
merscov
infect
role
still
limit
largescal
diseas
prevent
merscov
high
risk
area
therapeut
window
gener
narrow
mab
massscal
product
timeand
resourceconsum
vaccin
still
remain
best
choic
merscov
prevent
given
critic
role
mediat
viral
entri
major
target
neutral
antibodi
glycoprotein
rbd
becom
prime
target
merscov
immunogen
design
vaccin
develop
variou
approach
appli
twenti
vaccin
candid
report
past
year
includ
vaccin
base
inactiv
virion
viruslik
particl
recombin
viral
vector
dna
recombin
protein
subunit
nanoparticl
tabl
summar
critic
featur
approach
protect
potenti
experiment
anim
model
till
two
vaccin
candid
enter
human
clinic
trial
vaccin
first
test
healthi
human
volunt
dna
plasmid
encod
merscov
glycoprotein
requir
twotothre
inject
deliv
electropor
phase
clinic
trial
start
walter
reed
armi
institut
anoth
phase
iii
clinic
trial
conduct
korea
test
dosag
safeti
immunogen
anoth
vaccin
candid
replicationdefici
chimpanze
adenoviru
contain
merscov
glycoprotein
antigen
vaccin
requir
onetim
administr
viru
particl
via
intramuscular
rout
local
advers
event
well
immunogen
evalu
phase
clinic
trial
conduct
univers
oxford
addit
one
candid
vaccin
test
dromedari
camel
either
potenti
human
use
straight
veterinari
use
explor
modifi
vaccinia
viru
ankara
mva
vector
express
merscov
glycoprotein
regimen
involv
immun
intranas
well
intramuscular
rout
twice
interv
vaccin
camel
demonstr
signific
reduct
excret
infecti
viru
viral
rna
transcript
vaccin
anim
upon
merscov
challeng
protect
merscov
infect
correl
presenc
serum
neutral
antibodi
merscov
mva
establish
reason
good
safeti
profil
human
induc
desir
protect
immun
camel
repres
one
potenti
candid
evalu
human
near
futur
remain
vaccin
candid
stage
preclin
laboratori
develop
invari
target
glycoprotein
rbd
critic
viral
entri
tabl
vaccin
base
inactiv
viruslik
particl
histor
preced
induc
protect
immun
respons
human
whether
strategi
applic
merscov
requir
studi
particularli
come
possibl
safeti
concern
apart
mvabas
vaccin
test
dromedari
camel
vectorbas
approach
also
activ
pursu
includ
adenoviru
measl
viru
veev
replicon
particl
vesicular
stomat
viru
rabi
viru
recombin
virus
encod
merscov
antigen
demonstr
strong
immunogen
mice
nonhuman
primat
model
shown
confer
protect
merscov
challeng
mous
model
tabl
howev
concern
remain
regard
preexist
immun
viral
vector
natur
infect
would
diminish
vaccin
potenc
overcom
issu
preexist
immun
human
adenovirus
preserv
advantag
high
yield
strong
immunogen
rare
serotyp
chimpanze
adenoviru
low
human
seropreval
may
adopt
viral
vector
group
recent
develop
vaccin
candid
replicationdefect
chimpanze
adenoviru
vector
express
full
length
merscov
glycoprotein
seropreval
around
human
popul
much
lower
commonli
use
human
adenoviru
vector
one
intranas
administr
viral
particl
complet
protect
human
knockin
mice
lethal
merscov
challeng
passiv
transfer
immun
sera
confer
surviv
advantag
lethal
challeng
mous
model
safeti
profil
vector
yet
extens
test
human
recent
hashem
colleagu
show
adenovirusbas
vaccin
may
pose
potenti
safeti
concern
may
induc
pulmonari
perivascular
hemorrhag
merscov
challeng
mous
model
regardless
full
protect
upon
lethal
viral
infect
also
show
pulmonari
patholog
mitig
incorpor
immunemodul
therefor
potenti
molecular
adjuv
recombin
adenovirusbas
vaccin
whether
vaccineassoci
patholog
relat
residu
infecti
virus
unbalanc
immun
respons
await
investig
mind
futur
merscov
vaccin
candid
design
take
extra
caution
safeti
evalu
furthermor
recombinantproteinbas
vaccin
wide
pursu
strategi
solubil
merscov
glycoprotein
order
form
stabl
immunogen
includ
form
nanoparticl
use
solubl
protein
truncat
particular
nanoparticl
form
full
length
merscov
glycoprotein
subunit
rbdbase
vaccin
shown
induc
viru
neutral
antibodi
protect
mice
challeng
merscov
one
rbd
subunit
vaccin
also
confer
protect
rhesu
macaqu
indic
rbd
alon
antigen
may
suffici
protect
immun
develop
viru
along
find
mab
target
ntd
abl
neutral
merscov
lan
et
al
show
three
dose
intramuscularli
administ
recombin
ntd
protein
also
induc
protect
immun
live
merscov
human
transduc
mous
model
mice
recent
structur
insight
spike
glycoprotein
pallesen
et
al
develop
prefusionstabil
trimer
vaccin
substitut
prolin
residu
domain
introduct
prolin
disfavour
refold
linker
central
helix
thu
prevent
transit
spike
postfus
state
ration
design
antigen
mer
shown
induc
broader
potent
neutral
activ
wild
type
spike
trimer
protein
final
primeboost
strategi
base
fulllength
glycoprotein
dna
vaccin
follow
boost
abl
induc
virusneutr
antibodi
confer
protect
clinic
sever
diseas
nonhuman
primat
model
compar
proteinonli
regimen
combin
dna
protein
induc
function
divers
antibodi
repertoir
stronger
immun
respons
suggest
nativ
glycoprotein
conform
form
cell
surfac
dna
vaccin
help
induc
divers
antibodi
merscov
summar
tabl
aforement
strategi
requir
multipl
immun
may
pose
addit
logist
hurdl
end
point
use
unclear
whether
immun
strategi
empir
design
due
rel
abbrevi
anim
model
human
transgen
mice
globalepitheli
express
human
knockin
mice
replac
situ
mice
transduc
human
adenoviru
vector
express
mice
nonhuman
primat
nhp
efficaci
specif
anim
model
list
previou
column
studi
conduct
multianim
model
result
highestlevel
model
shown
neutral
antibodi
nab
indic
indic
less
poor
immunogen
candid
vaccin
practic
compliant
purpos
singl
immun
highest
immunogen
anim
human
prefer
outbreak
merscov
saudi
arabia
remind
us
sarscov
outbreak
china
despit
differ
geograph
locat
epidemiolog
immedi
anim
reservoir
two
virus
share
remark
similar
caus
sever
respiratori
syndrom
lead
high
fatal
human
trigger
seriou
public
health
concern
advent
modern
techniqu
virolog
immunolog
vaccinolog
gain
substanti
insight
biolog
merscov
pathogenesi
unpreced
speed
accuraci
summar
current
review
tremend
progress
made
understand
entri
process
merscov
target
cell
structur
function
glycoprotein
cellular
receptor
mediat
viral
entri
antibodi
respons
natur
infect
isol
broad
potent
neutral
mab
design
develop
vaccin
candid
use
variou
innov
technolog
howev
progress
translat
discoveri
clinic
applic
slow
two
vaccin
candid
one
mab
panel
enter
phase
clinic
trial
safeti
iron
vaccin
treatment
strategi
approv
sarscov
infect
even
decad
outbreak
could
imagin
catastroph
would
sarscov
hit
merscov
continu
probe
gain
strong
capac
transmiss
among
human
face
difficult
predica
come
public
health
challeng
new
era
emerg
reemerg
infecti
diseas
one
hand
human
popul
becom
ever
mobil
expos
increas
number
pathogen
hand
translat
basic
discoveri
prevent
treatment
applic
exceedingli
slow
among
mani
plausibl
reason
lack
incent
financi
return
perhap
stand
tallest
deadlock
happen
merscov
sarscov
also
mani
infecti
pathogen
ebola
marburg
lassa
highli
pathogen
avian
influenza
fundament
drastic
chang
made
entir
research
develop
system
truli
prepar
posit
ahead
deadli
epidem
pandem
speed
accuraci
basic
discoveri
time
translat
clinic
public
health
need
time
act
